Association of Serum BDNF with Severity of Cognitive Disorders in Patients with Type 2 Diabetes

Abstract

Background: Cognitive disorders are common in patients with type 2 diabetes mellitus (DM2) and affect the quality of life, work and social adaptation. Diagnosis of cognitive disorders is carried out using various tests, each of which has its own advantages and disadvantages. Aim: To study of the association between serum level of BDNF and the severity of cognitive disorders in patients with DM2. Materials and methods: Included in the study 61 patients with DM2 complicated by central neuropathy with cognitive disorders and 28 clinically healthy volunteers without DM2. The cognitive and depressive disorders were evaluated using the Montreal Cognitive Assessment (MoCA), Frontal Assessment Batter (FAB), Hospital Anxiety and Depression Scale (HADS). The serum level of BDNF was determined via the method of enzyme-linked immunosorbent assay ac[1]cording. Results: Cognitive disorders in patients with DM2 manifests in the form of disorders of spatial orientation, attention and short-term memory. Frontal dysfunction, mainly in the form of impaired conceptualization and grasping reflexes, was recorded in 30% of patients with DM2. The serum level of BDNF in patients with DM2 is significantly lower than in healthy volunteers and is associated with the duration of DM2, the serum level of HbA1c. Conclusion: Serum level of BDNF may by potential biochemical marker of metabolic cognitive disorders in DM2.